Alcoholic hepatitis

Unicycive Announces Multiple Abstracts Selected for Presentation at American Society of Nephrology’s Kidney Week 2022

Retrieved on: 
Wednesday, August 24, 2022
Literature, Enzyme, IgG4-related ophthalmic disease, Vance DeGeneres, COVID-19, Security (finance), Kidney, Safety, Hepatic encephalopathy, ASN, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Therapy, Chronic kidney disease, Coronavirus, Randomized controlled trial, SUR2, Phosphate binder, Hyperphosphatemia, Decision-making, Degenerative disease, Macular degeneration, Food, KATP, Acute kidney injury, Patent, Alcoholic hepatitis, U.S. Securities and Exchange Commission, Liver disease, FDA, Biotechnology, Nicorandil, Failure, 2021 Essex County Council election, AMD, Private Securities Litigation Reform Act, Oxidative stress, Patient, Pharmaceutical industry

All abstracts for ASNs Kidney Week 2022 will be available via the ASN website ( www.asn-online.org/education/kidneyweek ) by October 14, 2022.

Key Points: 
  • All abstracts for ASNs Kidney Week 2022 will be available via the ASN website ( www.asn-online.org/education/kidneyweek ) by October 14, 2022.
  • Renazorb has been shown to offer unique phosphate binding characteristics, which have the potential to treat hyperphosphatemia in chronic kidney disease patients.
  • Unicycive is preparing a clinical bioequivalence study performed in healthy volunteers in order to submit a 505(b)(2) new drug application to the U.S. Food and Drug Administration.
  • UNI-494 is a patent-protected new chemical entity in late preclinical development for the treatment of acute kidney injury.For more information, please visit www.unicycive.com .

Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-043 for Severe Alcoholic Hepatitis

Retrieved on: 
Monday, June 13, 2022
Retina, Kidney, Coronavirus, Fibrosis, Degenerative disease, Research, Lung, Cochlea, ADA, Pharmacokinetics, Central nervous system, Annual report, Forward-looking statement, GLP, Security (finance), Liver, Regeneration, U.S. Securities and Exchange Commission, Probability, Nasdaq, Therapy, Cirrhosis, Hepatitis, Soft tissue injury, GLOBE, Patient, Hearing loss, Mortality, Liver injury, Trial of the century, COVID-19, Institute of Liver and Biliary Sciences, Mouse, Antibody, Lists of diseases, Toxicology, Disease, Prevalence, SAN, Eye, Homeostasis, History, Tissue, Alcoholic hepatitis, Inflammatory bowel disease, AH, Safety, Pharmaceutical industry, WNT

The Phase 1, randomized, single and multiple ascending dose study will evaluate the safety, pharmacokinetics and activity of SZN-043.

Key Points: 
  • The Phase 1, randomized, single and multiple ascending dose study will evaluate the safety, pharmacokinetics and activity of SZN-043.
  • Our team has remained diligently focused on applying our Wnt research and platforms while rapidly advancing these uniquely engineered antibodies.
  • Surrozen is developing SZN-043 for severe liver diseases, initially focusing on severe alcoholic hepatitis.
  • The first subject in the Phase 1 clinical study of SZN-043 was dosed in June, and the trial is posted to the Australian New Zealand Clinical Trial Registry here .

Surrozen Presents Data on Lead Therapeutic Candidates at Digestive Disease Week (DDW)

Retrieved on: 
Tuesday, May 24, 2022
Epithelium, CEO, Inflammation, Degenerative disease, UC, Edu, Hyperplasia, Toxicology, Retina, Soft tissue injury, Disease, DDW, Ulcerative colitis, U.S. Securities and Exchange Commission, Homeostasis, Infection, Immunoglobulin G, Kinetics, Hearing loss, Coronavirus, GLP, Liver, FZD5, Cochlea, COVID-19, Trial of the century, SCID, Kidney, Research, IBD, Mouse, Inflammatory bowel disease, SAN, RATS, Alcoholic hepatitis, DSS, Probability, Fibrosis, Lists of disasters, Forward-looking statement, Tissue, Central nervous system, Major, Liver injury, Regeneration, Hepatocyte, Lists of diseases, Lung, Therapy, Security (finance), Eye, Annual report, Hepatitis, Institute of Liver and Biliary Sciences, GLOBE, Pharmaceutical industry, Medical imaging, Dietary supplement, WNT

These data represent the important progress and significant advances made in the scientific understanding of our lead therapeutic candidates, SZN-1326 and SZN-043, said Craig Parker, CEO of Surrozen.

Key Points: 
  • These data represent the important progress and significant advances made in the scientific understanding of our lead therapeutic candidates, SZN-1326 and SZN-043, said Craig Parker, CEO of Surrozen.
  • The data further show that SZN-1326 also reduced stromal and immune cytokine signaling and immune cell infiltration.
  • Surrozen is a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway.
  • However, while Surrozen may elect to update these forward-looking statements at some point in the future, Surrozen specifically disclaims any obligation to do so, except as required by law.

Surrozen Reports Fourth Quarter and Full Year 2021 Financial Results

Retrieved on: 
Thursday, March 24, 2022
Administration, Therapy, Liver injury, Lung, Institute of Liver and Biliary Sciences, AMD, Forward-looking statement, Lists of diseases, PK, Kidney, Soft tissue injury, Growth, Hearing loss, Coronavirus, Central nervous system, IND, Idiopathic pulmonary fibrosis, Liver, Hepatitis, Research, Toxicology, Ulcerative colitis, Diabetic retinopathy, Probability, Lists of disasters, Disease, Retinopathy, U.S. Securities and Exchange Commission, Tissue, Retina, Cochlea, Homeostasis, Security (finance), Regeneration, Inflammatory bowel disease, Inflammation, SWAP, Nasdaq, COVID-19, COPD, GLOBE, Fibrosis, SWEETS, Degenerative disease, Alcoholic hepatitis, Eye, SAN, Maintenance, Annual report, Idiopathic disease, Development, Insurance, Infection, Pharmaceutical industry, Dietary supplement, Vaccine, Medical imaging, WNT

Surrozen is initially developing SZN-1326 for moderate to severe ulcerative colitis in inflammatory bowel disease.

Key Points: 
  • Surrozen is initially developing SZN-1326 for moderate to severe ulcerative colitis in inflammatory bowel disease.
  • Following recent completion of IND-enabling GLP tox studies, Surrozen expects to initiate Phase 1 clinical trials of both SZN-1326 and SZN-043 in healthy volunteers in the third quarter of 2022.
  • The data included results from multiple disease models and species and were presented through 26 posters and oral presentations at 5 major medical meetings in 2021.
  • Financial Results for the Fourth Quarter Ended December 31, 2021
    Cash Position: Cash, cash equivalents and marketable securities were $123.5 million as of December 31, 2021, compared to $135.4 million as of September 30, 2021.

Surrozen Announces Key 2022 Milestones for Lead Programs and Acceleration of Research Pipeline

Retrieved on: 
Monday, January 10, 2022
Parker, Idiopathic pulmonary fibrosis, Tissue, SAN, Lists of disasters, Growth, AMD, Central nervous system, Disease, Retinopathy, FZD4, Hearing loss, Hepatitis, Eye, Security (finance), Coronavirus, Goal, Liver, Fibrosis, Institute of Liver and Biliary Sciences, Chronic obstructive pulmonary disease, IND, Lists of diseases, U.S. Securities and Exchange Commission, Acceleration, Duane syndrome, Regeneration, Lung, Inflammatory bowel disease, Alcoholic hepatitis, Cochlea, Diabetic retinopathy, Probability, Forward-looking statement, IPF, Liver injury, Retina, Research, Ophthalmology, Soft tissue injury, Degenerative disease, Nasdaq, Technology, Kidney, Homeostasis, Wnt signaling pathway, COVID-19, Infection, Therapy, GLOBE, Inflammation, Maintenance, COPD, Pharmaceutical industry, Vaccine, Medical imaging, WNT

SOUTH SAN FRANCISCO, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repair and regeneration, announced key development goals and acceleration of its research pipeline as the company transitions to a clinical-stage biotechnology company.

Key Points: 
  • 2022 promises to be a transformational year for Surrozen, as it marks our planned entry into the clinic for two novel therapeutic candidates, said Craig Parker, President and Chief Executive Officer of Surrozen.
  • Furthermore, we have expanded to a third therapeutic area in ophthalmology with the recent nomination of lead candidate SZN-413.
  • Parker continued, Our discovery programs continue to identify new areas where our Wnt platform technologies could have therapeutic impact, including lacrimal gland and lung.
  • SZN-1326 is the first development candidate designed using Surrozens SWAPTM technology and targets the Wnt signaling pathway in the intestinal epithelium.

Arrowhead Pharmaceuticals Enters Exclusive License Agreement with GSK for ARO-HSD

Retrieved on: 
Monday, November 22, 2021
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, Patient, Private Securities Litigation Reform Act, Alcoholic hepatitis, Security (finance), Liver disease, News, CEO, Mace Head Atmospheric Research Station, Safety, Sale, Organic acid, Annual report, Arrowhead Pharmaceuticals, Institute of Liver and Biliary Sciences, Hart–Scott–Rodino Antitrust Improvements Act, Mission statement, Hormone, The New England Journal of Medicine, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Pharmacokinetics, U.S. Securities and Exchange Commission, Metabolism, COVID-19, GSK, Arrowhead, Cirrhosis, SVP, ALT, Mutation, HSD17B13, GlaxoSmithKline, RNA, RNA transfection, NASH, China, RNA interference, Medicine, Fatty liver disease, Fibrosis, HSD, ARO, NASDAQ, Liver, Pharmaceutical industry

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it entered into an exclusive license agreement with GlaxoSmithKline (LSE/NYSE: GSK) under which GSK will develop and commercialize ARO-HSD, Arrowheads investigational RNA interference (RNAi) therapeutic in a Phase 1/2 trial that is currently being developed as a treatment for patients with nonalcoholic steatohepatitis (NASH).

Key Points: 
  • Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it entered into an exclusive license agreement with GlaxoSmithKline (LSE/NYSE: GSK) under which GSK will develop and commercialize ARO-HSD, Arrowheads investigational RNA interference (RNAi) therapeutic in a Phase 1/2 trial that is currently being developed as a treatment for patients with nonalcoholic steatohepatitis (NASH).
  • GSK has a global reach and impressive capabilities in the clinical development and commercialization of important medicines.
  • We look forward to enabling GSK to advance ARO-HSD towards the millions of patients worldwide who do not have adequate treatment options.
  • GSK will receive an exclusive license to develop and commercialize ARO-HSD in all territories except Greater China, which will be retained by Arrowhead.

Surrozen Reports Third Quarter 2021 Financial Results

Retrieved on: 
Monday, November 15, 2021
PIPE, Degenerative disease, Tissue, SAN, Kidney, Infection, Ulcerative colitis, Security (finance), Compte rendu, Cornea, Technology, Liver, Coronavirus, SWEETS, Insurance, Probability, Growth, Hearing loss, COVID-19, Lists of diseases, Research, Lists of disasters, Administration, U.S. Securities and Exchange Commission, Forward-looking statement, Inflammatory bowel disease, Alcoholic hepatitis, Institute of Liver and Biliary Sciences, Hepatitis, GLOBE, Development, Regeneration, Therapy, Homeostasis, Cochlea, Eye, Disease, Business architecture, Liver injury, Fibrosis, Lung, Central nervous system, Nasdaq, Soft tissue injury, Retina, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Surrozen or the Company) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update.
  • Financial Results for the Third Quarter Ended September 30, 2021
    Cash Position: Cash, cash equivalents and marketable securities were $135.4 million as of September 30, 2021, compared to $18.9 million as of June 30, 2021.
  • If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements.
  • There may be additional risks that Surrozen presently does not know, or that Surrozen currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements.

Doctor's Appointments for Alcohol Related Diseases Rose by 60% During the Pandemic Legacy Healing Center Responds

Retrieved on: 
Monday, November 15, 2021
Alcoholism, Anxiety, Fear, Substance abuse, Depression, Pancreatitis, Friends, CEO, Disease, Liver, COVID-19, Alcoholic hepatitis, Institute of Liver and Biliary Sciences, Social isolation, Behavioural sciences, Woman, Social, Mental health, Binge drinking, Quarantine, Public health, Pharmaceutical industry, Liquor

Alcohol-related diseases that are surging include cirrhosis of the liver, alcoholic hepatitis, pancreatitis, and gastritis all well-known health impacts of heavy and binge drinking.

Key Points: 
  • Alcohol-related diseases that are surging include cirrhosis of the liver, alcoholic hepatitis, pancreatitis, and gastritis all well-known health impacts of heavy and binge drinking.
  • Legacy Healing Center, a leading addiction treatment center in New Jersey and South Florida, worries that we will be dealing with the mental and emotional impacts of the pandemic for many years to come.
  • "The disease of addiction metastasizes in isolation," said Chief Clinical Officer and CEO of Legacy Healing Center , David Levin.
  • Behavioral health facilities like Legacy Healing Center in Cherry Hill that specialize in treating alcohol use disorder will play a key role in healing the mental and emotional aftermath of COVID-19.

Arrowhead Presents Additional Clinical Data on Investigational ARO-HSD Treatment at AASLD Liver Meeting

Retrieved on: 
Friday, November 12, 2021
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, ARO, Fatty liver disease, Safety, RNA interference, American Association, Hormone, Private Securities Litigation Reform Act, Organic acid, News, The New England Journal of Medicine, Investor, Cirrhosis, Security (finance), NASDAQ, RNA, Gene, TA, Mission statement, Trial of the century, Mutation, AASLD, COVID-19, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Gene silencing, Annual report, Alcoholic hepatitis, Institute of Liver and Biliary Sciences, Association, Arrowhead Pharmaceuticals, Twitter, HSD, NASH, Company, U.S. Securities and Exchange Commission, Annual general meeting, Metabolism, Therapy, Pharmacodynamics, Hospital, Pharmacokinetics, PNPLA3, Liver disease, Arrowhead, Patient, Poster, HSD17B13, Pharmaceutical industry, Vaccine

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced additional interim clinical data from AROHSD1001, an ongoing Phase 1/2 clinical study of ARO-HSD, the companys investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with alcohol-related and nonalcohol related liver diseases, such as nonalcoholic steatohepatitis (NASH).

Key Points: 
  • Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced additional interim clinical data from AROHSD1001, an ongoing Phase 1/2 clinical study of ARO-HSD, the companys investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with alcohol-related and nonalcohol related liver diseases, such as nonalcoholic steatohepatitis (NASH).
  • The data were presented in a late-breaking poster at The Liver Meeting, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD), taking place November 12-15, 2021.
  • ARO-HSD is an investigational RNAi therapeutic targeting HSD17B13 as a potential treatment for patients with alcohol-related and nonalcohol related liver diseases, such as NASH.
  • Additional exploratory objectives of AROHSD1001 include the assessment of various measures of drug activity using liver biopsy.

Liver Disease Patients Struggle with Healthy Habits During the Covid-19 Pandemic, Data Show

Retrieved on: 
Thursday, September 16, 2021
Snack, Fatty liver disease, Alcoholic hepatitis, Water, Liver, SCLC, Liver disease, American Association, GI, Patient, Meal, COVID-19, Habit, Liver transplantation, Disease, HIV disease progression rates, Association, Physician, Institute of Liver and Biliary Sciences, Asian Liver Center, Sodium, Diet, Vegetable, Awareness, Health, Dietary supplement, Animal

However, when the Covid-19 pandemic disrupted our daily lives, liver disease patients experienced a downturn in their healthy habits.

Key Points: 
  • However, when the Covid-19 pandemic disrupted our daily lives, liver disease patients experienced a downturn in their healthy habits.
  • Amsetys analysis shows that the diet and lifestyle habits of liver disease patients have significantly worsened since the beginning of the Covid-19 pandemic.
  • To understand the impact of the Covid-19 pandemic on the dietary and lifestyle habits of liver disease patients, Amsetythe first liver health nutrition company in the U.S.has analyzed the data of the Liver Health Score.
  • Long-term disruptions in healthy habits can cause disease progression and a surge of liver disease cases overall across the country.